








asof: 2026-09-14
The broker narrative shifted sharply from a defensive, post-earnings-miss tone in July 2023 — focused on margin contraction, FDF/API weakness, CDMO high-base drag, and estimate cuts — to a confident long-term growth story by July 2026 built on a ~70% CDMO ramp, 31.5% EBITDA margin, and aggressive capex/LPZ expansion. Persistent themes were CDMO strengthening and formulation/bio recovery, while the emphasis changed from near-term operating deleverage and earnings risk to sustainable CDMO mix, targeted capital deployment, and long-term R&D infrastructure.
16 broker calls · 2023-07-27 to 2026-07-26
Extracted from CNBC-TV18 posts; ratings and targets are as published, not current consensus. OCR may contain errors. Speaker attribution is retained; not all speakers are brokers. These statements are separate from the Broker Narrative and Broker Timeline and have no calculated performance or outcomes.
| Published / source (IST) | Speaker / affiliation | Rating / target | Commentary |
|---|---|---|---|
| 2026-11-17 |
Laurus Labs
Mgmt
|
—
|
Promoters have no plan for further stake sale. Stake sale was done to pay off debt and for philanthropy purposes. |
No recorded management comments with an explicit designation and affiliation for this ticker.
Copyright © 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.